Standard Chemotherapy Brings Longer Progression-Free Survival in Non-Small Cell Lung Cancer — Physician’s First Watch
Standard Chemotherapy Brings Longer Progression-Free Survival in Non-Small Cell Lung Cancer
By Kelly Young
Standard chemotherapy is associated with longer progression-free survival than the newer, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in certain patients with advanced non-small cell lung cancer, according to a JAMA meta-analysis.
Researchers analyzed 11 randomized, open-label trials that compared a conventional chemotherapy agent with a first-generation EGFR TKI, such as erlotinib or gefitinib, in 1600 patients with wild-type EGFR tumors. Standard chemotherapy brought a longer median progression-free survival than EGFR TKI treatment (6.4 vs. 1.9 months). However, there was no difference between the groups in overall survival.